Lessons From The First Biosimilar MAb Launch In Europe
Physicians appear more willing to prescribe Hospira’s Inflectra, a biosimilar version of J&J’s Remicade, to new patients in countries in Europe where it is available, but less inclined to switch patients already taking the brand. The company’s experience in Europe could offer lessons for manufacturers looking to bring biosimilars to market in the US.
You may also be interested in...
Differences in payer policies have limited the biosimilar opportunity in some EU nations; IMS report points to examples US should replicate or avoid as biosimilars are introduced domestically.
With two biosimilars set to move into Phase III this year, Oncobiologics hopes partnership with hospital services firm Premier will generate 'best practices around the optimal use of these cost-effective treatments.'
Data necessary for regulatory approval may not be sufficient for prescribers, Pfizer’s Sophie Opdyke tells Pharmaceutical Strategy Conference.